

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)

February 2008

BUDGET ACTIVITY		PE NUMBER AND TITLE							
4 - Advanced Component Development and Prototypes		0603807A - Medical Systems - Adv Dev							
COST (In Thousands)	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	FY 2012 Estimate	FY 2013 Estimate	Cost to Complete	Total Cost
Total Program Element (PE) Cost	22511	29689	26308	24537	10213	13916	13918	Continuing	Continuing
808 DOD DRUG & VACC AD	5914	6014	5668	5477	5384	6223	6033	Continuing	Continuing
811 MIL HIV VAC&DRUG DEV	144	149	149	141	140	148	152		1156
836 COMBAT MEDICAL MATL AD	3459	4347	13718	13261	3010	5768	5913	Continuing	Continuing
837 SOLDIER SYS PROT-AD	2439	1889	6773	5658	1679	1777	1820	Continuing	Continuing
A01 COMBAT SUPPORT HOSPITAL - MOBILE SURGICAL UNIT	3293	5961							13183
CS4 MEDICAL SYSTEMS ADV DEV INITIATIVES (CA)		7750							7750
MD4 FUTURE MEDICAL SHELTER	6294	1987							18391
MD8 ELECTROSOMOTIC PAIN THERAPY SYSTEM (CA)	968	1592							4476

A. Mission Description and Budget Item Justification: This program element (PE) funds advanced development of medical materiel within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle. The PE supports transition of Science and Technology initiatives, prototypes, or candidate technologies into the first scale-up, integrated models for initial technical and operational test and evaluation, when applicable. These programs are aligned to meet Future Force (F2) requirements stressed within concept documents and organizational structures. The PE provides funding for early Phase 1 and 2, U.S. Food and Drug Administration (FDA) regulated, human clinical trials. The major enablers supported by this PE are:

Infectious disease vaccines and preventive drugs that will reduce the risk of service members contracting debilitating or fatal diseases. Disease and non-battle injuries (DNBI) are the largest contributors to the level 3 medical footprint, and significant reductions of the medical footprint in theater is achieved by reducing the number of DNBI affected soldiers.

Combat Casualty Care devices and biologics, with two major focuses: enhance forward care at the first responder level and reduce the footprint of medical organizations for greater mobility and easier sustainment. The F2 concept places soldiers into a more austere environment with lengthened evacuation times (both arrival and transit). Supporting medics and first responders require greater lifesaving and extended stabilization capability to save lives. Reduction in weight, volume, and sustainment requirements, allows medical units to increase mobility.

Soldier Performance Enhancers in the form of drugs or diagnostics will allow commanders to assess the status of and increase soldier's cognitive awareness and stamina. Performance enhancers will increase soldier capabilities and reduce casualties resulting from suboptimal situational awareness.

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)

February 2008

BUDGET ACTIVITY

PE NUMBER AND TITLE

4 - Advanced Component Development and Prototypes

0603807A - Medical Systems - Adv Dev

Military Human Immunodeficiency Virus (HIV) Vaccine and Drug Development funds militarily relevant HIV medical countermeasures. These include advanced component development of multiple candidate vaccines and drugs for large-scale field testing.

This program is managed by the U.S. Army Medical Research and Materiel Command.

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)

February 2008

BUDGET ACTIVITY

PE NUMBER AND TITLE

4 - Advanced Component Development and Prototypes

0603807A - Medical Systems - Adv Dev

<u>B. Program Change Summary</u>	FY 2007	FY 2008	FY 2009
Previous President's Budget (FY 2008/2009)	23608	12479	21452
Current BES/President's Budget (FY 2009)	22511	29689	26308
Total Adjustments	-1097	17210	4856
Congressional Program Reductions		-190	
Congressional Rescissions			
Congressional Increases		17400	
Reprogrammings	-522		
SBIR/STTR Transfer	-575		
Adjustments to Budget Years			4856

Increase of \$17.4 Million in FY 08 due to Congressional adds:
 Project A01, Combat Support Hospital - Mobile Surgical Unit \$6 Million;
 Project MD4, Future Medical Shelter \$2 Million;
 Project MD8, Electrosomotic Pain Therapy System \$1.6 Million;
 Project CS4, Medical Systems Advanced Development Initiatives \$7.8 Million.

The \$4.856 Million budget adjustment to FY 09 refers to Project 837, Advanced Component Development and Prototypes. In Fy 09, based on a down-select process of leading hemorrhage treatment candidates, conduct initial clinical trials with selected candidate chosen from the following: freeze dried plasma, frozen platelets, complement inhibitors or novel resuscitation fluid.

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes		PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev					PROJECT 808			
COST (In Thousands)	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	FY 2012 Estimate	FY 2013 Estimate	Cost to Complete	Total Cost	
808 DOD DRUG & VACC AD	5914	6014	5668	5477	5384	6223	6033	Continuing	Continuing	

A. Mission Description and Budget Item Justification: This project funds technical development of candidate medical countermeasures for infectious diseases that occur within militarily relevant areas of the world. Current products fall within three major areas: vaccines, drugs, and diagnostic kits/devices. The funds support human clinical trials in a small (20-80) group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug is distributed, metabolized, and excreted from the body and to investigate the appropriate dose for therapeutic use. These funds support small-scale human clinical efficacy trials of the drug/vaccine in larger groups (20-300) and are designed to assess how well the drug works, as well as to continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits/devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis if contracted, and speeding recovery once diagnosed. These trials are required to meet U.S. Food and Drug Administration (FDA) regulatory approval guidance, a mandatory obligation for all military products placed into the hands of medical providers or service members. Priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).

<u>Accomplishments/Planned Program:</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>
Reviews, evaluations, and human clinical trials of malarial/anti-malarial vaccines, drugs, diagnostics and insect repellents: In FY07, for the anti-malarial drug, Tafenoquine (for treatment and post-exposure prophylaxis of Plasmodium vivax malaria) began development of the Integrated Safety Output document that is required for the investigational new drug file and completed the follow-up portion of the FDA-mandated expanded safety trial; monitored the anti-malarial drug, Artesunate as efficacy trials were started and the program prepared for a Critical Design Review (CDR); conducted a CDR for the Recombinant Plasmodium falciparum Malaria Vaccine plus Adjuvant (RTS,S) Vaccine which re-baselined the program in technology development to be administered with another Malaria vaccine candidate to enhance efficacy; and for Combined Camouflage Face Paint/Insect Repellent (CCFP) conducted two human clinical efficacy trials (laboratory and field) of the new stick formulations, began data analysis and prepared to evaluate the CCFP with insect repellent formulation against textile materials & equipment items. In FY08, complete the Integrated Safety Output document for Tafenoquine, prepare a report on the expanded safety trial, and begin planning for a human clinical efficacy trial in Asia; continue Artesunate's human efficacy trials and conduct a CDR; and complete the analysis for CCFP's field efficacy trials and report on compatibility of materials.. In FY09, continue clinical trials for Artesunate; for Tafenoquine continue preparing for an human clinical efficacy trial in Asia; and for CCFP finalize technical reports and conduct a Milestone C to transition to Full-Rate Production and Deployment, resulting in fielding of state-of-the-art camouflage face paint with insect repellent in stick packaging; and conduct a Milestone B for a new standard military topical insect repellent to transition into System Development and Demonstration phase.	2244	2732	2778
Trials, evaluations, and reviews for grouped infectious disease vaccines and drugs (Dengue and Leishmania): In FY07, conducted a Critical Design Review (CDR) to re-baseline product development plan, continued the Phase 1/2 lot bridging study in the United States, initiated a Phase 2 trial in Puerto Rico, and continued Thailand Phase 2 safety trial of the Dengue Tetraivalent Vaccine (DTV); conducted a CDR to re-baseline product development plan, completed the Tunisian Phase 2 trial, manufactured additional drug, and prepared for the	3670	3151	2890

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2008

BUDGET ACTIVITY	PE NUMBER AND TITLE	PROJECT	
4 - Advanced Component Development and Prototypes	0603807A - Medical Systems - Adv Dev	808	
<p>Phase 3 pivotal field trial of the Paromomycin/Gentamicin Topical Antileishmanial Cream; for Pentostam (sodium stibogluconate intravenous drug treatment of cutaneous leishmaniasis) completed clinical database verification for transfer to industry partner who will incorporate in their FDA licensure submission package; and for the Congressional-interest Leishmania Skin Test(LST) completed a Phase 2 trial in Tunisia and initiated data analysis. In FY08, for DTV complete the Phase 1/2 lot bridging study, continue the Phase 2 trials in Puerto Rico and Thailand, and initiate pre-trial activities for an expanded Thailand Phase 2 safety and efficacy trial; for Topical Antileishmanial initiate the Phase 3 pivotal trial in Tunisia and continue stability testing; for Pentostam monitor industry partner's progress with FDA licensure submission; and for the LST finalize the Phase 2 trial clinical report, initiate a Phase 2 safety trial in the United States, and continue stability studies. In FY09, for DTV complete the Thailand Phase 2 safety trial and initiate data analysis, continue Puerto Rico Phase 2 trial, and initiate expanded Thailand Phase 2 safety and efficacy trial; continue Tunisia Phase 3 pivotal trial for Topical Antileishmanial Cream; for Pentostam continue to monitor industry partner's FDA licensure submission; and for LST complete the Phase 2 safety trial and perform data analysis.</p>			
Small Business Innovative Research/Small Business Technology Transfer Programs.		131	
Total	5914	6014	5668

B. Other Program Funding Summary Not applicable for this item.

C. Acquisition Strategy Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.

ARMY RDT&E COST ANALYSIS (R3)

February 2008

BUDGET ACTIVITY			PE NUMBER AND TITLE							PROJECT		
4 - Advanced Component Development and Prototypes			0603807A - Medical Systems - Adv Dev							808		
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			4848	577		545		512		Cont.	Cont.	Cont.
Subtotal:			4848	577		545		512		Cont.	Cont.	Cont.
II. Support Costs	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			1032	193		182		171		Cont.	Cont.	Cont.
Subtotal:			1032	193		182		171		Cont.	Cont.	Cont.
III. Test And Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			25116	4369		4358		4099		Cont.	Cont.	Cont.
Subtotal:			25116	4369		4358		4099		Cont.	Cont.	Cont.
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			5486	775		929		886		Cont.	Cont.	
Subtotal:			5486	775		929		886		Cont.	Cont.	

ARMY RDT&E COST ANALYSIS (R3)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes	PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev						PROJECT 808			
Project Total Cost:	36482	5914		6014		5668		Cont.	Cont.	Cont.

Schedule Profile (R4 Exhibit)

February 2008

BUDGET ACTIVITY	PE NUMBER AND TITLE																PROJECT											
4 - Advanced Component Development and Prototypes	0603807A - Medical Systems - Adv Dev																808											
Event Name	FY 07				FY 08				FY 09				FY 10				FY 11				FY 12				FY 13			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Anti-Malarial, Tafenoquine (CDR)	Critical Design Review				▲ ₁																							
(2) Antimalarial, Artesunate (CDR)	Critical Design Review				▲ ₂																							
(3) Combined Camouflage Face Paint/Insect Repellant (MS-C)					MS-C				▲ ₃																			
(4) Dengue Tetravalent Vaccine (CDR)	Critical Design Review				▲ ₄																							
(5) Paromomycin/Gentamicin Topical Antileishmanial Cream (CDR)	Critical Design Review				▲ ₅																							
(6) Leishmania Skin Test (CDR)					Critical Design Review				▲ ₆																			
(7) New Standard Military Topical Insect Repellant (MS-B)									MS-B				▲ ₇															

Schedule Detail (R4a Exhibit)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes		PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev					PROJECT 808	
<u>Schedule Detail</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2011</u>	<u>FY 2012</u>	<u>FY 2013</u>	
Anti-Malarial, Tafenoquine (CDR)		4Q						
Antimalarial, Artesunate (CDR)		4Q						
Combined Camouflage Face Paint/Insect Repellant (MS-C)			1Q					
Dengue Tetravalent Vaccine (CDR)		3Q						
Paromomycin/Gentamicin Topical Antileishmanial Cream (CDR)		3Q						
Leishmania Skin Test (CDR)			3Q					
New Standard Military Topical Insect Repellant (MS-B)			4Q					

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes		PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev						PROJECT 836	
COST (In Thousands)	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	FY 2012 Estimate	FY 2013 Estimate	Cost to Complete	Total Cost
836 COMBAT MEDICAL MATL AD	3459	4347	13718	13261	3010	5768	5913	Continuing	Continuing

A. Mission Description and Budget Item Justification: This project funds technical development of candidate medical products for the advancement of combat casualty care; especially far forward on the battlefield for first responders, combat life savers, and field medics. The primary objective is to fund initial human clinical trials for safety and efficacy of devices unique to military operational requirements. These products will provide the necessary materiel and devices to support combat casualty care and reduce mortality rates. Additionally, these products may reduce the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. The products that provide the greatest clinical benefit balanced with the technical and financial risks determine the priority of development.

Major contractors/intra-governmental agencies include: IGR Enterprises, Army Medical Department Board Test Center, SeQual Technologies, Inc., and Enginivity, Inc.

Accomplishments/Planned Program:

	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>
Conduct/Perform development, testing and Milestone reviews for field medical treatment and treatment aid devices: (1) Ceramic Oxygen Generator (COG): In FY07, conducted technical environmental testing to determine ruggedness of oxygen cells. (2) Rotary Valve Pressure Swing Adsorption Oxygen Generator (RVPSAOG): FY07, conducted evaluation of new air compressor concept for Omni II system. Began construction of new prototype. In FY08, conduct technical testing of Omni II. (3) Battery Powered IV Fluid Warmer: In FY07, found COTS battery acceptable for battery-powered model. Conducted user evaluation of battery-powered unit. (4) Future Medical Shelter System (FMSS): FY07, conducted user evaluation. FY08, develop engineering development models. In FY09, conduct down-select to one system. (5) Future Combat System (FCS): In FY07, continued to provide consulting to PM-UA. In FY08, continue to provide consulting to PM-UA. (6) Ultrasonic Brain Imager (UBI): FY07, began contracting efforts to begin testing and evaluation of prototype system. In FY08, begin technical testing and evaluation of scope of prototype resolution and capabilities. In FY09, begin clinical user assessments. In FY09 for a hemorrhage treatment candidate, based on a down-select, conduct a Milestone B (transition into System Development and Demonstration phase) and begin a safety and efficacy human clinical trial with the leading hemorrhage treatment candidate chosen from the following: Freeze Dried Plasma, Frozen Platelets, complement inhibitors or novel resuscitation fluid.	3459	4269	13718
Small Business Innovative Research/Small Business Technology Transfer Programs		78	
Total	3459	4347	13718

B. Other Program Funding Summary Not applicable for this item.

C. Acquisition Strategy Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.

ARMY RDT&E COST ANALYSIS (R3)

February 2008

BUDGET ACTIVITY			PE NUMBER AND TITLE							PROJECT		
4 - Advanced Component Development and Prototypes			0603807A - Medical Systems - Adv Dev							836		
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No other contract exceeds \$1M			13459	75		87		276			13897	
Subtotal:			13459	75		87		276			13897	
II. Support Costs	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
Subtotal:												
Remarks: No product/contract costs greater than \$1M individually.												
III. Test And Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
Subtotal:												
Remarks: No product/contract costs greater than \$1M individually.												
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.			21676	3384		4260		13442			42762	
Subtotal:			21676	3384		4260		13442			42762	
Project Total Cost:			35135	3459		4347		13718			56659	

Schedule Profile (R4 Exhibit)

February 2008

BUDGET ACTIVITY
4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE
0603807A - Medical Systems - Adv Dev

PROJECT
836

Event Name	FY 07				FY 08				FY 09				FY 10				FY 11				FY 12				FY 13			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Ceramic Oxygen Gen, (2) Rotary Valve Pressure Oxygen Generator (MS-B), (3) Electro-osmotic Pain Therapy system (EPTS) (MS B)	MS B ▲ ₁				MS B ▲ ₂				MS B ▲ ₃																			

Schedule Detail (R4a Exhibit)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes		PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev					PROJECT 836	
<u>Schedule Detail</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2011</u>	<u>FY 2012</u>	<u>FY 2013</u>	
Ceramic Oxygen Gen	4Q							
Rotary Valve Pressure Oxygen Generator (MS-B)		3Q						
Electro-osmotic Pain Therapy system (EPTS) (MS B)			3Q					
Hemorrhage Treatment Candidate								

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes		PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev						PROJECT 837	
COST (In Thousands)	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	FY 2012 Estimate	FY 2013 Estimate	Cost to Complete	Total Cost
837 SOLDIER SYS PROT-AD	2439	1889	6773	5658	1679	1777	1820	Continuing	Continuing

A. Mission Description and Budget Item Justification: This project supports the conceptual and technical development of preventive medicine materiel including devices and medicines in order to provide protection, sustainment, and enhancement of the physical and psychological capabilities of soldiers across the Army's full spectrum operations. Focus is on the reduction of personnel losses due to preventable disease and non-battle injuries through the development of environmental and physiological performance monitors and other preventive medicine countermeasures.

Accomplishments/Planned Program:	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>
Coliform Analyzer: In FY07, conducted technical tests for certification. In FY08, conduct user tests and evaluations. Conduct DRR. In FY09, conduct technical testing and user evaluations. Resuscitation Fluids: Environmental Sentinel Biomonitor: In FY09, conduct Milestone B.	2439	1836	6773
Small Business Innovative Research/Small Business Technology Transfer Programs		53	
Total	2439	1889	6773

B. Other Program Funding Summary Not applicable for this item.

C. Acquisition Strategy Test and evaluate materiel in-house and commercially developed preventative medicine materiel to meet FDA and EPA regulatory requirements.

ARMY RDT&E COST ANALYSIS (R3)

February 2008

BUDGET ACTIVITY			PE NUMBER AND TITLE							PROJECT		
4 - Advanced Component Development and Prototypes			0603807A - Medical Systems - Adv Dev							837		
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			2178	1094		863		3228		Cont.	Cont.	
Subtotal:			2178	1094		863		3228		Cont.	Cont.	
II. Support Costs	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			137	75		57		205		Cont.	Cont.	
Subtotal:			137	75		57		205		Cont.	Cont.	
III. Test And Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually		Research and development; stability and potency testing	643	473		361		1227		Cont.	Cont.	
Subtotal:			643	473		361		1227		Cont.	Cont.	
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2007 Cost	FY 2007 Award Date	FY 2008 Cost	FY 2008 Award Date	FY 2009 Cost	FY 2009 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			1390	797		608		2113		Cont.	Cont.	

ARMY RDT&E COST ANALYSIS (R3)

February 2008

BUDGET ACTIVITY	PE NUMBER AND TITLE						PROJECT	
4 - Advanced Component Development and Prototypes	0603807A - Medical Systems - Adv Dev						837	
Subtotal:	1390	797		608		2113	Cont.	Cont.
Project Total Cost:	4348	2439		1889		6773	Cont.	Cont.

Schedule Profile (R4 Exhibit)

February 2008

BUDGET ACTIVITY	PE NUMBER AND TITLE																PROJECT											
4 - Advanced Component Development and Prototypes	0603807A - Medical Systems - Adv Dev																837											
Event Name	FY 07				FY 08				FY 09				FY 10				FY 11				FY 12				FY 13			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Coliform Analyzer (MS-B)					MS B ▲																							

Schedule Detail (R4a Exhibit)

February 2008

BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes		PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev					PROJECT 837	
<u>Schedule Detail</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2011</u>	<u>FY 2012</u>	<u>FY 2013</u>	
Coliform Analyzer (MS-B)		3Q						
Environmental Sentinel Biomonitor (2nd QTR FY 09)								